How A Drugmaker Gamed The System To Keep Generic Competition Away

Updated 11:16 EDT: This story now includes information about the Food and Drug Administration’s release of a list of complaints against brand-name drugmakers for hindering access to samples for generic testing. When Celgene Corp. first started marketing the drug Revlimid to treat multiple myeloma in 2006, the price was $6,195 for 21 capsules, a month’s supply.

Categories: News Feed Tags: Tags: ,

The Best Fix for Drug Prices Is Already on the Books

The Drug Price Competition and Patent Term Restoration Act – better known as Hatch-Waxman – was signed into law by President Ronald Reagan 34 years ago. Sponsored by Senator Orrin Hatch of Utah, a devout conservative, and Representative Henry Waxman of California, a flaming liberal, its primary purpose was to make drugs more affordable by kick-starting the relatively new generic drug industry.

Categories: News Feed Tags: Tags: ,

A Supreme Court victory for lowering drug prices

A recent Supreme Court decision on patents – Oil States v. Greene’s Energy Group marks an understated victory, with far-reaching consequences that will positively impact families and communities across America. This case has deep implications for basic economic fairness, with the judiciary recognizing the importance of keeping critical checks in systems that have become far too imbalanced.

Categories: News Feed Tags: Tags: ,

Drug pricing: A regulatory tug of war

The pharmaceutical industry has suggested to the central government that it should increase its reviewing powers on the decisions taken by National Pharmaceutical Pricing Authority (NPPA). The regulator is learnt to have responded with a contrarian view that the government should “abandon its archaic practice of reviewing NPPA orders” and, instead, establish an independent appellate tribunal.

4 NCR hospitals jacked up prices of branded drugs 12 fold: NPPA

Some hospitals in the National Capital Region (NCR) prescribed branded medicines that were outside the regulator’s purview and inflated their prices several times in order to boost profit, the National Pharmaceutical Pricing Authority said. Four hospitals in the NCR marked up the retail prices of such medicines as much as 12-fold from the rates at which they were purchased, NPPA said in a report.

NPPA analysis: Three private hospitals earn huge margins on drugs

NPPA analysis: Three private hospitals earn huge margins on drugs | The Indian Express National Pharmaceutical Pricing Authority (NPPA) on Tuesday came out with a price analysis of three unnamed private hospitals in the city that showed huge margins on MRPs kept by these hospitals on drugs and consumables, ranging from 2112 per cent to 116 per cent.